IL6 and rheumatoid arthritis: Similar studies have been conducted in other immunological diseases; in rheumatoid arthritis, ADA treatment resulted in reductions in plasma levels of chemerin, correlated with decreases in IL-6 and macrophage migration inhibitory factor concentrations [29].